Panel to discuss new data regarding TP53 mutations and prostate cancer risk
“Our case discussion for January 18 is going to be focused on a patient who initially has biochemically recurrent prostate cancer [and] progresses to metastatic disease,” says Veda N. Giri, MD.
In this video, Veda N. Giri, MD, offers a preview of the ENGAGEMENT Study Virtual Genetics Board’s upcoming case discussion focusing on new data on TP53 mutations and prostate cancer risk as well as TP53-related management. which you can sign up for by going to www.prostategenetics.com/engagement. The event will take place on January 18 at 12 pm ET. Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Mistrust of medical research may discourage genetic testing in prostate cancer
November 20th 2023According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.
